Scholarlink

<p>The <i>APOE</i> locus is the strongest genetic factor for Alzheimer’s disease, with ε4 increasing and ε2 decreasing risk, yet the basis of these opposing effects remains unclear. Here we performed a multicohort proteomic analysis across plasma and cerebrospinal fluid in GNPC, BioFINDER-2, ADNI, UK BioBank, and PPMI. <i>APOE</i>-associated protein alterations are detectable before amyloid pathology and remain stable across age and disease progression. <i>APOE2</i>-associated proteins were enriched in pathways related to cellular maintenance and anti-inflammatory processes. By contrast, <i>APOE4</i> showed a limited set of upstream mediators linked to cell-cycle and oligodendrocyte precursor cell biology, and a broader group of proteins reflecting vascular, immune, and proteostatic dysfunction shaped by downstream pathology. Comparative analyses highlighted allele-specific mediators and oppositely regulated proteins contributing to differential disease risk. Together, these findings reveal that <i>APOE2</i> and <i>APOE4</i> shape Alzheimer’s disease risk through distinct molecular architectures and identify candidate biomarkers and targets for allele-specific interventions.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Proteomic signatures of the APOE ε4 and APOE ε2 genetic variants and Alzheimer’s disease

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月15日

查看全文
  • Lina Lu,
  • Alexa Pichet Binette,
  • Ines Hristovska,
  • Shorena Janelidze,
  • Bart Smets,
  • Irene Cumplido-Mayoral,
  • Aparna Vasanthakumar,
  • Britney Milkovich,
  • Lijun An,
  • Rik Ossenkoppele,
  • Varsha Krish,
  • Farhad Imam,
  • Sebastian Palmqvist,
  • Jacob W. Vogel,
  • Erik Stomrud,
  • Oskar Hansson,
  • Niklas Mattsson-Carlgren

摘要

The APOE locus is the strongest genetic factor for Alzheimer’s disease, with ε4 increasing and ε2 decreasing risk, yet the basis of these opposing effects remains unclear. Here we performed a multicohort proteomic analysis across plasma and cerebrospinal fluid in GNPC, BioFINDER-2, ADNI, UK BioBank, and PPMI. APOE-associated protein alterations are detectable before amyloid pathology and remain stable across age and disease progression. APOE2-associated proteins were enriched in pathways related to cellular maintenance and anti-inflammatory processes. By contrast, APOE4 showed a limited set of upstream mediators linked to cell-cycle and oligodendrocyte precursor cell biology, and a broader group of proteins reflecting vascular, immune, and proteostatic dysfunction shaped by downstream pathology. Comparative analyses highlighted allele-specific mediators and oppositely regulated proteins contributing to differential disease risk. Together, these findings reveal that APOE2 and APOE4 shape Alzheimer’s disease risk through distinct molecular architectures and identify candidate biomarkers and targets for allele-specific interventions.